Abstract | BACKGROUND: METHODS: The authors studied 290 patients with untreated MM who received IMiD-based initial therapy, including 123 patients who received thalidomide- dexamethasone (TD) and 167 patients who received lenalidomide- dexamethasone (LD) induction before SCT. Patients who underwent a stem cell harvest attempt were considered transplantation-eligible and were included. SCT within 12 months of diagnosis and within 2 months of harvest were considered early SCT (n = 173; 60%). SCT >12 months after diagnosis was considered delayed SCT (n = 112; 40%). RESULTS: In the delayed SCT group, 42 patients had undergone SCT at the time of the current report, and the median estimated time to SCT was 5.3 months and 44.5 months in the early SCT and delayed SCT groups, respectively. The 4-year overall survival rate from diagnosis was 73% in both groups (P = .3) and was comparable in those who received TD (68% vs 64%, respectively) and those who received LD (82% vs 86%, respectively) as initial therapy. The time to progression after SCT was similar between the early and delayed SCT groups (20 months vs 16 months; P value nonsignificant). CONCLUSIONS:
|
Authors | Shaji K Kumar, Martha Q Lacy, Angela Dispenzieri, Francis K Buadi, Suzanne R Hayman, David Dingli, Francesca Gay, Shirshendu Sinha, Nelson Leung, William Hogan, S Vincent Rajkumar, Morie A Gertz |
Journal | Cancer
(Cancer)
Vol. 118
Issue 6
Pg. 1585-92
(Mar 15 2012)
ISSN: 1097-0142 [Electronic] United States |
PMID | 22009602
(Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 American Cancer Society. |
Chemical References |
|
Topics |
- Adult
- Aged
- Female
- Hematopoietic Stem Cell Transplantation
- Humans
- Immunologic Factors
(therapeutic use)
- Male
- Middle Aged
- Multiple Myeloma
(mortality, therapy)
- Survival Rate
- Transplantation, Autologous
|